San Jose, CA, United States of America

Xinwei Wang

USPTO Granted Patents = 6 


Average Co-Inventor Count = 5.3

ph-index = 3

Forward Citations = 165(Granted Patents)


Location History:

  • San Jose, CA (US) (2004 - 2011)
  • Germantown, MD (US) (2014)

Company Filing History:


Years Active: 2004-2014

Loading Chart...
Loading Chart...
6 patents (USPTO):

Title: Innovations of Xinwei Wang: A Pioneer in PCSK9 Antagonists

Introduction

Xinwei Wang, an accomplished inventor based in San Jose, California, stands out in the field of biopharmaceuticals with a remarkable portfolio of six patents. His groundbreaking work primarily focuses on the development of antagonists targeting human proprotein convertase subtilisin-kexin type 9 (PCSK9), a key player in cholesterol regulation and cardiovascular health.

Latest Patents

Wang's latest patents include innovative treatments utilizing PCSK9 antagonists. The AX132 and AX1 patents detail the design and application of these antagonists, which effectively inhibit PCSK9 function. This inhibition is crucial for the treatment of various conditions associated with heightened PCSK9 activity. These patents not only disclose the antagonists but also describe the nucleic acid encoding them, vectors, host cells, and the compositions that include these antagonists. Furthermore, methodologies regarding the production of PCSK9-specific antagonists and their usages in inhibiting or antagonizing PCSK9 function are substantively addressed.

Career Highlights

Throughout his career, Xinwei Wang has contributed to significant advancements in the field of biomedicine. His experience includes engagement with notable companies such as Abmaxis, Inc. and Merck Sharp & Dohme Corporation. Through these roles, he has been instrumental in translating scientific research into viable therapeutic solutions, reflecting his commitment to innovation.

Collaborations

Wang's inventive journey has been bolstered by collaborations with talented professionals in the industry. Notably, he has worked alongside Pingyu Zhong and Caili Wang, each bringing unique expertise to their projects. These collaborations have enabled the sharing of ideas and enhanced the effectiveness of their research efforts.

Conclusion

In conclusion, Xinwei Wang’s inventive spirit and dedication to developing PCSK9 antagonists have positioned him as a key figure in the fight against cardiovascular diseases. His ongoing research and patents continue to pave the way for innovative treatments that may significantly impact patient care and health outcomes in the future. With a strong foundation built on collaboration and career milestones, Wang remains a vital contributor to the landscape of medical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…